January 23, 2019
A further non-exclusive licence to the Company’s stroke biomarker patent portfolio was completed on 22 January 2019 with Galaxy CCRO Inc. (“Galaxy”), a recently formed US clinical contract research organisation, which intends to develop a point of care test for the diagnosis and timing of stroke onset in order to direct patients to specialists who can administer thrombolytic treatment. Under the terms of the licence Proteome Sciences will receive equity in Galaxy as an initial licence fee, with subsequent development milestones and a running royalty on product sales. Galaxy CCRO Inc announcement